Kit for removing rivaroxaban in plasma in vitro

A rivaroxaban and kit technology, applied in the field of biomedicine, can solve the problems of large thrombosis risk, test results misleading clinical diagnosis and treatment, false positives, etc.

Pending Publication Date: 2021-11-19
PEOPLES HOSPITAL PEKING UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These two types of tests will be interfered by rivaroxaban, causing false positives or false negatives, seriously affecting clinical diagnosis and treatment
[0003] Currently, patients taking rivaroxaban need to stop taking the drug for two weeks to detect lupus anticoagulant substances. The test results are seriously misleading clinical diagnosis and treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit for removing rivaroxaban in plasma in vitro
  • Kit for removing rivaroxaban in plasma in vitro
  • Kit for removing rivaroxaban in plasma in vitro

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] The present invention provides a kit for removing rivaroxaban from blood plasma. The kit includes: test tube ①: 10 mg of medical-grade activated carbon powder; test tube ②: an empty tube.

[0022] When using it, you can follow the steps below: (1) Treatment of patient’s plasma: process the plasma according to the method of lupus anticoagulant detection in the laboratory, or according to the instructions of the lupus anticoagulant detection reagent (centrifuge at 1500gl for 10min, repeat twice). (2) Take out 500-1000 microliters of the processed plasma directly and place it in the test tube ①, and mix it upside down at room temperature for 5 minutes. (3) Centrifuge the test tube ① for 2 minutes, take the supernatant and put it in the test tube ②, then centrifuge the test tube ② for 2 minutes, the supernatant after centrifugation is the plasma without rivaroxaban, which can be directly used for the detection of lupus anticoagulant substances .

Embodiment 2

[0023] Embodiment 2 condition screening experiment

[0024] Screening of the ratio of activated carbon to plasma, mixing time and centrifugal force:

[0025] The ratio of activated carbon and plasma in the detection method in Example 1, the mixing time of activated carbon and plasma, and the centrifugation conditions in step 3 are replaced accordingly according to those in Table 1, and the other steps are reported unchanged to process plasma and process After the plasma was tested for lupus anticoagulant substances. Among them, the ratio of activated carbon to plasma (5:1000; 10:1000; 15:1000), mixing time (2min; 5min; 7min), centrifugal force (1000r / min; 2000r / min; 3000r / min). Each group was repeated 20 times, and the results are shown in Table 1. It was concluded that there was no difference in the removal efficiency of rivaroxaban between the two ratios of 10:1000 and 15:1000. The amount is less than 10:1000. For different centrifugal forces, the removal rate is obviousl...

Embodiment 3

[0029] 1) Normal fresh frozen plasma obtained from the blood transfusion department (the plasma does not contain rivaroxaban or lupus anticoagulant substances), and about 10-15 parts each time are mixed into normal mixed plasma, and a total of 20 mixed plasmas are obtained, each 10ml. After two times of centrifugation at 1500g for 10 minutes, the supernatant was obtained to obtain platelet-poor plasma (PLT<10*109 / L).

[0030] 2) The platelet-poor mixed plasma obtained in step 1) was divided into four groups, the first group took 1ml without any treatment; the second group took 1ml and carried out kit treatment by the method described in Example 1; the third group was Prepare 2ml each of rivaroxaban plasma (200ng / ml, 400ng / ml, 600ng / ml, 800ng / ml) with four concentrations of rivaroxaban standard substance. After preparation, take 1ml of each concentration and use Example 1 As the fourth group after the kit treatment was carried out according to the method described in .

[003...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a kit for removing rivaroxaban in plasma, the kit comprises at least two independent test tubes, and at least one of the test tubes is filled with activated carbon. The invention provides a simple and easy-to-implement scheme, the scheme depends on an activated carbon adsorption function, rivaroxaban in detected plasma of a patient can be removed, blood coagulation factors in the plasma cannot be influenced, and lupus anticoagulant substance detection based on a coagulation method is not influenced by rivaroxaban any more.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a kit for removing rivaroxaban in plasma in vitro. Background technique [0002] According to statistics, the incidence of antiphospholipid syndrome (APS) in the population is about 5 / 10,000. (APS) patients need to routinely use anticoagulants due to their hypercoagulable state. Currently, rivaroxaban is used as a direct oral anticoagulant in the It is widely used in clinical practice. At the same time, APS patients need to routinely detect the level of lupus anticoagulant substances to guide clinical treatment. This detection method is based on the coagulation method. At present, there are two main methods, one is to activate coagulation factor X through diluted snake venom (dRVVT), The coagulation time from coagulation factor X to fibrin formation is monitored to determine whether there are lupus anticoagulant substances; the other is to activate coagulation factor XII through silic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N1/28G01N1/34G01N33/86
CPCG01N1/28G01N1/34G01N33/86
Inventor 陆松松李梦努尔扎特·胡尔曼丁庆明徐秦竹宋英
Owner PEOPLES HOSPITAL PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap